Similar articles for PMID: 38981628

Year	Number of Results
2011	1
2013	2
2014	9
2015	19
2016	19
2017	23
2018	14
2019	13
2020	9
2021	4
2022	3
2023	1
2024	1
2026	0

1

Assessment of clinician adherence to Fingolimod instructions and its effect on patient safety.

Alhubaishi AA, Alsharekh LM, Almoharb HF, Alqarni FA, Alqahtani AM, Alghazwni MK, Alfuraydi MA, Alsadi AZ, Altalhi RY, Almutairi TM, Alshehri GH. Alhubaishi AA, et al. Neurosciences (Riyadh). 2024 Jul;29(3):184-189. doi: 10.17712/nsj.2024.3.20240040. Neurosciences (Riyadh). 2024. PMID: 38981628 Free PMC article.

2

A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.

Mitsikostas DD, Orologas A, Dardiotis E, Fakas N, Doskas T, Karageorgiou K, Maltezou M, Iliopoulos I, Vikelis M, Grigoriadis N. Mitsikostas DD, et al. Adv Ther. 2023 May;40(5):2217-2233. doi: 10.1007/s12325-022-02388-8. Epub 2023 Mar 10. Adv Ther. 2023. PMID: 36897520

3

Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study.

Bourdin A, Schneider MP, Locatelli I, Schluep M, Bugnon O, Berger J. Bourdin A, et al. Sci Rep. 2021 Feb 18;11(1):4107. doi: 10.1038/s41598-021-83220-1. Sci Rep. 2021. PMID: 33603005 Free PMC article.

4

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.

Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, Frider N, Alvarenga R. Ordoñez-Boschetti L, et al. Adv Ther. 2015 Jul;32(7):626-35. doi: 10.1007/s12325-015-0224-2. Epub 2015 Jul 14. Adv Ther. 2015. PMID: 26170105 Free PMC article. Clinical Trial.

5

The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.

Freedman MS, Duquette P, Grand'Maison F, Lee L, Vorobeychik G, Lara N, Khurana V, Nakhaipour HR, Schecter R, Haddad P. Freedman MS, et al. Curr Med Res Opin. 2019 May;35(5):767-776. doi: 10.1080/03007995.2019.1565818. Epub 2019 Jan 21. Curr Med Res Opin. 2019. PMID: 30614288

6

Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.

Meca-Lallana JE, Oreja-Guevara C, Muñoz D, Olascoaga J, Pato A, Ramió-Torrentà L, Meca-Lallana V, Hernández MA, Marzo ME, Álvarez-Cermeño JC, Rodríguez-Antigüedad A, Montalbán X, Fernández O; Spanish GILENYA Registry Investigators. Meca-Lallana JE, et al. PLoS One. 2021 Oct 13;16(10):e0258437. doi: 10.1371/journal.pone.0258437. eCollection 2021. PLoS One. 2021. PMID: 34644366 Free PMC article.

7

Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan.

Yang CC, Ro LS, Tsai NW, Lin CC, Huang WN, Tsai CP, Lin TS, Su JJ, Huang CC, Lyu RK, Chen HH, Lee WJ, Chen PL, Yang A. Yang CC, et al. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):542-550. doi: 10.1016/j.jfma.2020.07.002. Epub 2020 Jul 12. J Formos Med Assoc. 2021. PMID: 32669233 Free article.

8

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.

Cascione M, Tenenbaum N, Wendt J, Meng X, Schofield L, Cree BAC; PREFERMS investigators. Cascione M, et al. Mult Scler Relat Disord. 2018 Oct;25:50-56. doi: 10.1016/j.msard.2018.07.014. Epub 2018 Jul 11. Mult Scler Relat Disord. 2018. PMID: 30036854 Free article. Clinical Trial.

9

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.

Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M, Cooke K, Yuksel O. Achiron A, et al. BMC Neurol. 2017 Aug 7;17(1):150. doi: 10.1186/s12883-017-0913-3. BMC Neurol. 2017. PMID: 28784108 Free PMC article.

10

Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.

Lapierre Y, O'Connor P, Devonshire V, Freedman MS, Kremenchutzky M, Yeung M, Schecter R. Lapierre Y, et al. Can J Neurol Sci. 2016 Mar;43(2):278-83. doi: 10.1017/cjn.2015.325. Epub 2016 Jan 25. Can J Neurol Sci. 2016. PMID: 26890887

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38981628

100 results

Results by year